
Promakhos Therapeutics
Promakhos Therapeutics is a YC Summer 2021 (S21) company. Based in Boston, MA, USA. Team of 2.
About Promakhos Therapeutics
Summary
Promakhos Therapeutics develops a platform of bacterial molecules designed to restore the immune system's natural ability to control inflammation, rather than suppressing it. The company targets chronic inflammatory diseases, with Crohn's disease as its first indication, followed by type 1 diabetes and multiple sclerosis. Current standard-of-care therapies manage symptoms by dampening immune activity; Promakhos aims to address the underlying dysfunction instead.
From the Y Combinator listing
A therapeutics platform for curing inflammatory disorders
We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.
Facts
- Healthcare / Healthcare -> Therapeutics
- Boston, MA, USA
- 2
- Active
- Early
Founders (2)
- Jasper Edgar Neggers
- Katerina Chatzi
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works